NUMA1 and urinary bladder cancer: The National Institute for Health and Care Excellence (NICE) bladder cancer guidelines do not specify investigations in patients with haematuria, but they do recommend that patients with a new diagnosis of bladder cancer should undergo one of the following: urine cytology; an alternative urinary biomarker test (such as UroVysion using fluorescence in situ hybridization [FISH], ImmunoCyt or nuclear matrix protein 22 [NMP22]); photodynamic diagnosis; or narrow‐band imaging 4.